CV Sciences Reports Q3 Revenue and Product Launch

CV Sciences ( (CVSI) ) has issued an update.

CV Sciences, Inc., a leader in consumer wellness products, reported a third-quarter 2024 revenue of $3.9 million, slightly down from the previous year. Despite facing a challenging market, the company successfully launched a new line of cannabinoid-free supplements, further securing its top position in the hemp extract sector. With a focus on innovation and cost efficiency, CV Sciences is poised for future growth, aiming to enhance shareholder value and profitability through strategic acquisitions and product development.

For a thorough assessment of CVSI stock, go to TipRanks’ Stock Analysis page.